CY1111740T1 - Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων - Google Patents
Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιωνInfo
- Publication number
- CY1111740T1 CY1111740T1 CY20111100737T CY111100737T CY1111740T1 CY 1111740 T1 CY1111740 T1 CY 1111740T1 CY 20111100737 T CY20111100737 T CY 20111100737T CY 111100737 T CY111100737 T CY 111100737T CY 1111740 T1 CY1111740 T1 CY 1111740T1
- Authority
- CY
- Cyprus
- Prior art keywords
- trp
- missing
- phe
- lys
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Αποκαλύπτεται μια ποικιλία συζευγμάτων πεπτιδίων που αναπαρίστανται από τον ακόλουθο γενικό χημικό τύπο (I): R1-Z-X-Z΄-R2, όπου το Χ αναπαριστά ένα εξαπεπτίδιο του γενικού χημικού τύπου (II): A1-A2-A3-A4-A5-A6 όπου το Α1 αναπαριστά Arg, Lys, ή His, το Α2 αναπαριστά Tyr, Trp ή Phe, το Α3 αναπαριστά Tyr, Asn, Trp ή Phe, το Α4 αναπαριστά Lys, Arg ή His, το Α5 αναπαριστά Phe, Tyr, Trp, Leu, Val ή Ιle, και το Α6 αναπαριστά Arg, Lys, ή His και όπου το κάθε ένα κατάλοιπο αμινοξέος στο εν λόγω εξαπεπτίδιο μπορεί να είναι στην L ή D μορφή· το Ζ αναπαριστά μια άλυσο φορτισμένου πεπτιδίου από 4 έως 20 κατάλοιπα αμινοξέων έχοντας την D ή L χωροδιάταξη ή λείπει˙ και το Ζ̕ αναπαριστά μια άλυσο φορτισμένου πεπτιδίου από 4 έως 20 κατάλοιπα αμινοξέων έχοντας την D ή L χωροδιάταξη ή λείπει, παρεχομένου του γεγονότος ότι δεν λείπουν αμφότερα τα Ζ και Ζ'· το R1 αναπαριστά Η ή μια ακυλομάδα· το R2 αναπαριστά NR3R4 όπου το κάθε ένα εκ των R3 και R4 αναπαριστά ανεξαρτήτως υδρογόνο, C(1-6)αλκοξυομάδα, αρυλοξυομάδα, ή ένα κατώτερο αλκύλιο ως ορίζεται εις το παρόν· ή το R2 αναπαριστά ΟΗ· τα δε συζεύγματα πεπτιδίων του χημικού τύπου (I) όντας προαιρετικώς και περαιτέρω συνδεδεμένα σε μια οντότητα μεταφοράς· και τα άλατα, ένυδρα άλατα και επιδιαλυτωμένα άλατα εξ αυτών, και τα C-τελικώς αμιδομένα ή εστεροποιημένα παράγωγα εξ αυτών με κατάλληλα οργανικά ή ανόργανα οξέα, συμπεριλαμβανομένων των μεθόδων παρασκευής τέτοιων συζευγμάτων. Παρέχονται επίσης και αντισώματα που δεσμεύονται συγκεκριμένα στα συζεύγματα πεπτιδίων. Η παρούσα εφεύρεση έχει ένα ευρύ φάσμα σημαντικών εφαρμογών συμπεριλαμβανομένης της χρήσης στην αγωγή διαταραχών που επηρεάζονται από την νοσισεπτίνη και τα σχετικά παρόμοια με οπιοειδή πεπτίδια.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200000944 | 2000-06-16 | ||
DKPA200001485 | 2000-10-05 | ||
US25167100P | 2000-12-06 | 2000-12-06 | |
EP01952155A EP1294746B1 (en) | 2000-06-16 | 2001-06-15 | Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111740T1 true CY1111740T1 (el) | 2015-10-07 |
Family
ID=27222400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100737T CY1111740T1 (el) | 2000-06-16 | 2011-07-28 | Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1294746B1 (el) |
JP (1) | JP4624639B2 (el) |
AT (1) | ATE508138T1 (el) |
AU (1) | AU7294401A (el) |
CA (1) | CA2410224C (el) |
CY (1) | CY1111740T1 (el) |
DE (1) | DE60144561D1 (el) |
WO (1) | WO2001098324A1 (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550425B2 (en) | 2000-06-16 | 2009-06-23 | Zealand Pharma A/S | Diuretic peptide conjugates |
US7244701B2 (en) | 2000-06-16 | 2007-07-17 | Zealand Phama A/S | Diuretic peptide conjugate |
WO2003030828A2 (en) * | 2001-10-09 | 2003-04-17 | Synvax, Inc. | Nociceptin-based analgesics |
WO2003097857A2 (en) * | 2002-05-17 | 2003-11-27 | Zealand Pharma A/S | Method for the detection of aquaretic compounds |
US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
JP2006514649A (ja) * | 2003-12-17 | 2006-05-11 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 腎症の治療および予防のための組成物 |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
US9150618B2 (en) | 2010-10-14 | 2015-10-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
WO2012065082A1 (en) * | 2010-11-11 | 2012-05-18 | Massachusetts Institute Of Technology | Dendrimer-based excipients for the attentuation of protein aggregation |
WO2013091670A1 (en) * | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
KR20160023669A (ko) | 2013-06-26 | 2016-03-03 | 자이겐 인플라메이션 리미티드 | 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도 |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
US20160235807A1 (en) | 2013-10-09 | 2016-08-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
CN103936838B (zh) * | 2014-04-10 | 2015-10-28 | 武汉启瑞科技发展有限公司 | 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用 |
GB201506380D0 (en) | 2015-04-15 | 2015-05-27 | Serodus Asa | Materials and methods for treatment of pulmonary hypertension |
JP2024513651A (ja) * | 2021-02-26 | 2024-03-27 | ニューヨーク ユニバーシティ | 共有結合性ペプチドコンジュゲートに結合する抗体を含む組成物及び方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
AU2712999A (en) * | 1998-03-05 | 1999-09-20 | Novo Nordisk A/S | Use of hexapeptides for the manufacture of a pharmaceutical composition for the treatment of hot flushes |
NZ506839A (en) * | 1998-03-09 | 2003-05-30 | Zealand Pharma As | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
CN1981873A (zh) * | 2000-06-09 | 2007-06-20 | 莱古伦公司 | 制备微胶粒的方法和所述微胶粒的用途 |
US7459539B2 (en) * | 2000-12-15 | 2008-12-02 | Agensys, Inc. | Antibody that binds zinc transporter protein 108P5H8 |
-
2001
- 2001-06-15 AU AU7294401A patent/AU7294401A/xx active Pending
- 2001-06-15 EP EP01952155A patent/EP1294746B1/en not_active Expired - Lifetime
- 2001-06-15 AT AT01952155T patent/ATE508138T1/de active
- 2001-06-15 WO PCT/US2001/019113 patent/WO2001098324A1/en active IP Right Grant
- 2001-06-15 CA CA2410224A patent/CA2410224C/en not_active Expired - Fee Related
- 2001-06-15 JP JP2002504279A patent/JP4624639B2/ja not_active Expired - Fee Related
- 2001-06-15 DE DE60144561T patent/DE60144561D1/de not_active Expired - Lifetime
-
2011
- 2011-07-28 CY CY20111100737T patent/CY1111740T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2410224A1 (en) | 2001-12-27 |
EP1294746B1 (en) | 2011-05-04 |
CA2410224C (en) | 2013-08-13 |
AU7294401A (en) | 2002-01-02 |
JP2004516811A (ja) | 2004-06-10 |
EP1294746A1 (en) | 2003-03-26 |
DE60144561D1 (de) | 2011-06-16 |
JP4624639B2 (ja) | 2011-02-02 |
WO2001098324A8 (en) | 2002-03-21 |
WO2001098324A1 (en) | 2001-12-27 |
ATE508138T1 (de) | 2011-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111740T1 (el) | Συζευγματα πεπτιδιων ν- και/ή c-τελικως τροποποιημενα μεσω βραχεων αλυσων φορτισμενων πεπτιδιων | |
ES2194861T3 (es) | Peptidos opiodes. | |
TW251274B (el) | ||
EP0299402A3 (en) | Lhrh antagonists, their manufacture and pharmaceutical clhrh antagonists, their manufacture and pharmaceutical compositions thereof ompositions thereof | |
ZA919387B (en) | Bombesin antagonists | |
AU759442B2 (en) | Novel LHRH antagonists with improved solubility characteristics | |
GB1570210A (en) | Peptides | |
NZ335879A (en) | Somatostatin antagonist peptides having a D-amino acid at the second residue | |
DK0745093T3 (da) | Hidtil ukendte oligopeptoder med affinitet til opioidreceptorer | |
US4087419A (en) | Heptapeptides and methods for their production | |
CA1181395A (en) | Lh-rh antagonists | |
CS207570B2 (en) | Method of making the tetradecapeptide | |
KR870007206A (ko) | 폴리펩타이드 화합물 | |
IT1256247B (it) | Peptidi ciclici | |
KR850006940A (ko) | 레닌 억제제의 제조방법 |